Holen Sie sich die Stockscreener-App
609.94
0.33%
2.01
Handel nachbörslich:
603.54
-6.40
-1.05%
Schlusskurs vom Vortag:
$607.93
Offen:
$612.07
24-Stunden-Volumen:
2.32M
Relative Volume:
2.57
Marktkapitalisierung:
$63.95B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
14.86
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
-0.25%
1M Leistung:
-3.13%
6M Leistung:
-18.53%
1J Leistung:
+18.76%
1-Tages-Spanne:
$598.19
$616.24
1-Wochen-Bereich:
$598.19
$620.00
52-Wochen-Spanne:
$506.38
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story - Trefis
Regeneron Pharmaceuticals Inc (REGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Regeneron Pharmaceuticals Inc (REGN) Institutional Confidence - TradingKey
Regeneron Pharmaceuticals Inc (REGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Announces Key Outcomes from 202 - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Regeneron shareholders elect directors and approve key proposals at annual meeting - Investing.com
Regeneron (NASDAQ: REGN) holders back board, auditor and pay plan - Stock Titan
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
This Stock Is Up 58% This Year. Is It too Late to Buy? - The Motley Fool
Regeneron Pharmaceuticals Stock (US75811P1003): Analyst coverage and fundamentals in focus - AD HOC NEWS
Regeneron Pharma Stock (US75886F1075): Valuation In Focus After Recent Pullback - AD HOC NEWS
Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations - simplywall.st
(REGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN) Shareholder/Analyst CallSlideshow (NASDAQ:REGN) 2026-06-12 - Seeking Alpha
REGN: All board proposals passed as strong growth and pipeline advances were highlighted - TradingView
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Parabilis Medicines closes $770.5m IPO, Regeneron investment By Investing.com - Investing.com Canada
Regeneron backs Parabilis (PBLS) with IPO private placement and new charter - Stock Titan
Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance Singapore
Regeneron Keeps Biotech Execution In Focus Amid Market Volatility - Kalkine Media
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now? - Insider Monkey
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy - BioPharma Dive
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron backed Parabilis seeks up to $476M in US IPO - MSN
Is Incyte a Better Buy Than Regeneron Pharmaceuticals? - Trefis
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Regeneron-backed Parabilis rises on market debut (REGN:NASDAQ) - Seeking Alpha
Parabilis Medicines Raises $670 Million in Initial Public Offering - Pharmaceutical Executive
How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron’s (REGN) Antibody Therapy Gains WHO Support During Ebola Outbreak - Insider Monkey
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO - marketscreener.com
Parabilis Medicines (PBLS) launches IPO with $75M Regeneron private placement - Stock Titan
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight - Barchart.com
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
5 Best Healthcare Stocks to Buy with Highest Upside Potential - Insider Monkey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Daiwa Securities Group Inc. Sells 2,058 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court - Law360
Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading - AD HOC NEWS
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.63%
3.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):